Abstract
The prospect of in utero gene therapy presents both tremendous opportunities and real concerns. With the possibility of first clinical trials as little as two years away, now is the time to discuss the merits of this new technology. In this spirit, we present arguments for and against the development and application of human in utero gene therapy.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Billings, P. In utero gene therapy: The case against. Nat Med 5, 255–256 (1999). https://doi.org/10.1038/6457
Issue Date:
DOI: https://doi.org/10.1038/6457
This article is cited by
-
The ethics of human gene transfer
Nature Reviews Genetics (2008)
-
Immune responses to adeno-associated virus and its recombinant vectors
Gene Therapy (2003)
-
The ethical challenges of in utero gene therapy
Nature Genetics (2000)
-
Successful expression of β-galactosidase and factor IX transgenes in fetal and neonatal sheep after ultrasound-guided percutaneous adenovirus vector administration into the umbilical vein
Gene Therapy (1999)
